LONGITUDINAL CAPACITY REPORT
M. ALVAREZ · MRN 40233-CGenerated Jul 16, 2026 · UnDun Health
PATIENT CAPACITY REVIEW
Maria Alvarez
72 yrs · Female · GLP-1 agonist · Reporting period Apr–Jul 2026 (12 weeks)
Patient view ↗
COMPOSITE · vs BASELINE
−0.9%
▼ Locomotion declining · non-responder
UNDUN INTELLIGENCE · SUMMARY
Composite is −0.9%, but the signal is locomotion: down −3.1% where the GLP-1 cohort averages +5.2%, with weight −9.1% and step cadence −7%. This is the fingerprint of lean-mass loss. Logged protein is low and no resistance training is recorded.
FLAGGED THIS CYCLE
LOCOMOTION −3.1%
RECOMMENDED ACTION
Message the patient; reduce GLP-1 one step and add a protein target plus resistance training to protect lean mass. Order a DEXA.
Concise view. Switch to Standard for domains and trajectory, or Comprehensive for the full workup: heat map, aging projection, intervention impact and labs.
Capacity by domain
| DOMAIN | vs BASELINE | 12-WK TREND | STATUS |
|---|---|---|---|
| Locomotion | −3.1% | declining | MEANINGFUL |
| Vitality | −1.2% | easing | STABLE |
| Cognitive | +0.3% | holding | STABLE |
| Psychological | −0.4% | stable | STABLE |
| Sensory | 0.0% | stable | STABLE |
Composite is the mean of the five domain scores, each expressed as percent from personal baseline.
Composite trajectory
Composite capacity, percent from personal baseline. Steady decline since initiation; no responder uplift by week 8.
INTERVENTION TIMELINE
GLP-1 start
Suggested care plan
PRIORITY · REVIEW
UNDUN INTELLIGENCE · DECISION SUPPORT
Objective: Preserve lean mass while keeping the metabolic benefit of GLP-1.
MEDICATION
Step GLP-1 down one dose level; hold further escalation for 8 weeks.
NUTRITION
Set protein target 1.6 g/kg/day; refer to dietitian.
TRAINING
Add progressive resistance training 2–3×/week.
LABS
Order DEXA or bioimpedance to quantify lean vs fat mass.
FOLLOW-UP
Recheck locomotion and body composition in 4 weeks.
Draft plan generated by UnDun Intelligence. Requires clinician review and sign-off before it takes effect.
Signed Date
Wearable vitals
Weight−9.1%
Step cadence−7%
Daily steps4,200
Resting heart rate+2 bpm
Data coverage96%
Active interventions
GLP-1 agonistWEEK 8
Adherence 94%. Non-responder pattern; expected locomotion uplift absent.
Nutrition (self-directed)LOW PROTEIN
Logged protein well below target; no resistance training recorded.
Week-by-week detail
W1
W2
W3
W4
Composite
−0.4
−0.6
−0.7
−0.9
Locomotion
−1.4
−2.2
−2.7
−3.1
Vitality
−0.5
−0.9
−1.0
−1.2
Cognitive
+0.1
+0.2
+0.3
+0.3
Psychological
−0.2
−0.3
−0.3
−0.4
Sensory
0.0
0.0
0.0
0.0
Each domain by week, percent from baseline. Composite is the row mean.
Sleep & recovery
Avg sleep duration7.0 h
In range
Sleep consistency82%
Good
Deep sleep1.1 h
15% of night
REM sleep1.4 h
20% of night
Resting HR+2 bpm
Stable
HRV (rMSSD)−3%
Stable
Body composition & activity
Weight−9.1%
Fast — 8 weeks
Lean mass−4.4%
Likely muscle loss
Body fat−3.0%
Down
Step cadence−7%
Slowing
Avg daily steps4,200
Low
Logged proteinBelow target
No resistance training
Measured intervention effect
Composite capacity in the four weeks before versus after each intervention started, isolating its measured effect.
| INTERVENTION | 4-WK PRE | 4-WK POST | Δ |
|---|---|---|---|
| GLP-1 agonist | +0.2% | −2.6% | −2.8% |
Projected intervention impact
Estimated effect of each lever at target adherence, with the projected years of function preserved. Illustrative, model-based projections.
LOCOMOTION · STRENGTH
+8%
above baseline
4 yrs
delayed symptoms
Resistance training
2–3× weekly resistance+6%
Progressive load+2%
LEAN MASS
+4%
above baseline
2 yrs
delayed symptoms
Protein optimization
1.6 g/kg/day protein+3%
Dietitian-guided plan+1%
Domain heat map
On track
Watch
Concerning
Locomotion
Vitality
Cognitive
Psychological
Sensory
12 wk agonow
Weekly capacity status by domain, relative to personal baseline. Amber marks drift; red marks a crossed threshold.
Aging trajectory projection
YOUR TRAJECTORY
REFERENCE AGING
SYMPTOM THRESHOLD
Muscle loss accelerates the projection; reaches the symptom threshold near age 76 unless lean mass is protected.
Recent labs & biomarkers
| MARKER | VALUE | REF RANGE | FLAG |
|---|---|---|---|
| Albumin | 3.6 g/dL | 3.8–5.0 | LOW |
| HbA1c | 6.1% | 4.8–5.6 | HIGH |
| Creatinine | 0.6 mg/dL | 0.6–1.1 | LOW |
| ApoB | 79 mg/dL | <90 | — |
| Vitamin D | 28 ng/mL | 30–50 | LOW |
| eGFR | 88 | >60 | — |
Most recent panel on file. Flags are relative to standard reference ranges, not personalized targets.
Reviewing clinician: Dr. A. Okafor · UnDun Health. This report summarizes passively collected wearable and body-composition data interpreted against the patient's own baseline. UnDun Intelligence findings are decision-support hypotheses, not diagnoses, and do not replace clinical judgment.